Condition
Invasive Aspergillosis
Invasive aspergillosis is a serious infection where Aspergillus mold, breathed in from the air, grows in the lungs and can spread, mostly in people with weakened immune defenses. Caspofungin has moderate evidence, and some people whose infection resisted other antifungals responded to it. That rested on a small trial of under 100 patients, and because it slows fungal growth rather than killing it, it has mostly been used after other options.
Sources: PMID 12384840
- Updated
- How we grade
- 42 studies cited
- Supplements studied
- 0
- Medicines and peptides
- 1
- Graded outcomes
- 1
No supplement studies yetWe haven’t found supplement studies for Invasive Aspergillosis. The medicines and peptides studied for it are listed below.
Prescription medicines and peptides studied, for context
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Invasive Aspergillosis (Salvage) FDA-approved for refractory invasive aspergillosis based on Phase 2 trial (<100 patients). Response in patients failing other antifungals. Fungistatic mechanism limits first-line use. | Improves (the measure goes up) | Moderate effect | 35 studies | |||
Studies that measured invasive aspergillosis (salvage)
| ||||||
Key findings
- Invasive Aspergillosis (Salvage)Improves (the measure goes up)
Studies cited
42 studies from PubMed
- Efficacy and safety of voriconazole and caspofungin for the treatment of invasive pulmonary aspergillosis in critically ill patients in China.
- Rezafungin vs caspofungin for the treatment of invasive candidiasis: A systematic review and meta-analysis.
- Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection.
- Efficacy and safety of caspofungin for patients with hepatic insufficiency.
- Pharmacokinetics/Pharmacodynamics of Caspofungin in Plasma and Peritoneal Fluid of Liver Transplant Recipients.
- Caspofungin Effects on Electrocardiogram of Mice: An Evaluation of Cardiac Safety.
- Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.
- Factors influencing caspofungin plasma concentrations in kidney transplant patients with high incidence of invasive fungal infections.
- Caspofungin: a review of its characteristics, activity, and use in intensive care units.
- Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide.
- Adsorption and caspofungin dosing during continuous renal replacement therapy.
- Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.
- Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis.
- Successful treatment with caspofungin of candiduria in a child with Wilms tumor; review of literature.
- Efficacy and safety of caspofungin in children: systematic review and meta-analysis.
- Pharmacokinetics and safety of intravitreal caspofungin.
- Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: a meta-analysis of randomized controlled trials.
- Efficacy and safety of caspofungin in obese patients.
- Caspofungin therapy in immunocompromised children and neonates.
- Synthesis of the antifungal beta-1,3-glucan synthase inhibitor CANCIDAS (caspofungin acetate) from pneumocandin B0.
- Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials.
- Echinocandin antifungals: review and update.
- Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.
- Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
- Caspofungin: a review of its use in the treatment of fungal infections.
- Caspofungin: the first agent available in the echinocandin class of antifungals
- Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia
- Caspofungin: first approved agent in a new class of antifungals
- In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates
- Caspofungin: the first representative of a new antifungal class.
- Caspofungin: the first in a new class of antifungal agents.
- Echinocandin antifungal drugs.
- [New antifungal agents: voriconazole and caspofungin].
- Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
- Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
- Caspofungin: an echinocandin antifungal agent
- Caspofungin: an echinocandin antifungal agent.
- The role of caspofungin and the echinocandins in the antifungal armamentarium.
- Safety and tolerability of caspofungin acetate in the treatment of fungal infections
- Caspofungin for the treatment of esophageal candidiasis
- Caspofungin acetate: an antifungal agent.
- Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.